You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Article metrics

Article menu

This article has a correction. Please see:

XML
Clinical/translational cancer immunotherapy
Original research
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

 

Online download statistics by month:

Online download statistics by month: December 2020 to July 2025

AbstractFullPdf
Dec 2020344344127
Jan 2021593593255
Feb 2021389389118
Mar 2021323323138
Apr 2021289289106
May 202131831895
Jun 202122922970
Jul 202122022070
Aug 202122422581
Sep 2021239240107
Oct 2021216216120
Nov 2021260261143
Dec 202120921379
Jan 202222224077
Feb 202218219277
Mar 202222624788
Apr 202220022592
May 202225927197
Jun 2022294312163
Jul 202218118487
Aug 202220120875
Sep 202217317996
Oct 202215516681
Nov 202216016190
Dec 2022949545
Jan 202323123360
Feb 202315515869
Mar 202313513649
Apr 202311411559
May 202314414460
Jun 202311711845
Jul 202312412650
Aug 202310610629
Sep 202315415652
Oct 202321421660
Nov 202339539561
Dec 202314914942
Jan 2024858642
Feb 202413713841
Mar 202422422894
Apr 202418418568
May 202414514548
Jun 202413213247
Jul 202418618865
Aug 202418318451
Sep 202420520552
Oct 202418518946
Nov 202419519654
Dec 202417917998
Jan 202519920363
Feb 202533333443
Mar 202520620648
Apr 202522022061
May 202513713835
Jun 202511111130
Jul 2025220
Total11486116614199